Pentavac 0.5ml Vaccine

• Prevention of Tetanus
• Prevention of Pertussis
• Prevention of Diphtheria
• Prevention of Hepatitis B infection
• Prevention of Haemophilus influenzae Type b disease

Undesired symptoms or responses vary from individual to individual as the human body reacts differently to the Pentavac 0.5ml Vaccine  , but they disappear naturally within a few days as the body adjusts to the vaccine, which requires no medical attention. In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team.

Some of the common side effects of the vaccine are:

• Loss of appetite
• Irritation
• Injection site reactions (pain, swelling, redness)
• Skin rash
• Fever

• The Pentavac 0.5ml Vaccine is given into the thigh muscles of infants. It is an intramuscular injection. Do not use the same injection or syringe for another vaccine, as there is a chance of interaction. This vaccine is given routinely to infants in three doses at 6, 10, and 14 weeks of age.
• It is an adsorbed liquid formulation that is ready to use. Always consult your doctor before taking the vaccine, especially if you have a family history of blood disorders, heart problems, lung problems, pain in the limbs, or kidney problems. Also, let the medical healthcare team know if your child is allergic to any medicine.​​
  

Pentavac 0.5ml is a vaccine that contains the toxoid of tetanus, diphtheria, the surface antigen of hepatitis B, and the whole cell of pertussis bacteria, all of which are adsorbed on an adjuvant made of aluminum to trigger the immune response.

When this vaccine is given to an individual then it stimulates the immune system to produce specific antibodies against the toxins, but doesn’t cause disease. These antibodies and memory cells formed after taking the injection identify and counteract the toxins and generate memory for it, and neutralize it with a stronger immune response upon subsequent exposure within a few hours. This provides immunity within 2 to 4 weeks and for many years.

• Desai, S., Rathi, N., Kawade, A., Venkatramanan, P., Kundu, R., Lalwani, S. K., ... & Kulkarni, P. S. (2018). Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine. Vaccine, 36(37), 5519-5523. https://pubmed.ncbi.nlm.nih.gov/30104114/
• Bagattini, A. M., Quarti, M. M., S. Martinez-Silveira, M., Policena, G., E. Coelho, L., M. Luz, P., ... & M. Toscano, C. (2022). Systematic review of immunogenicity and duration of immunity of currently licensed pertussis wP vaccines in children. Gates Open Research, 6, 101. https://pmc.ncbi.nlm.nih.gov/articles/PMC11679829/
• Zepp, F., Knuf, M., Heininger, U., Jahn, K., Collard, A., Habermehl, P., ... & Sänger, R. (2004). Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine, 22(17-18), 2226-2233. https://pubmed.ncbi.nlm.nih.gov/15149781/
• Li, Y., Li, R. C., Ye, Q., Li, C., Liu, Y. P., Ma, X., ... & Mesaros, N. (2017). Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants. Human vaccines & immunotherapeutics, 13(3), 588-598. https://pubmed.ncbi.nlm.nih.gov/27768515/
• Klein, N. P., Abu-Elyazeed, R., Cheuvart, B., Janssens, W., & Mesaros, N. (2019). Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States. Human Vaccines & Immunotherapeutics, 15(4), 809-821. https://pmc.ncbi.nlm.nih.gov/articles/PMC6605854/